Cellectis (NASDAQ:CLLS) Releases Quarterly Earnings Results, Misses Estimates By $0.22 EPS

Cellectis (NASDAQ:CLLS) announced its earnings results on Thursday. The biotechnology company reported ($0.16) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.06 by ($0.22), Zacks reports. The company had revenue of $33.22 million for the quarter, compared to analysts’ expectations of $5.90 million. Cellectis had a negative net margin of 234.39% and a negative return on equity of 74.55%.

Cellectis Stock Down 3.9 %

CLLS stock opened at $1.24 on Friday. The stock’s fifty day simple moving average is $1.53 and its two-hundred day simple moving average is $1.83. The company has a current ratio of 1.78, a quick ratio of 1.78 and a debt-to-equity ratio of 0.48. Cellectis has a 1-year low of $1.14 and a 1-year high of $3.38. The stock has a market cap of $68.92 million, a P/E ratio of -0.95 and a beta of 3.27.

Analyst Upgrades and Downgrades

Separately, StockNews.com started coverage on Cellectis in a research report on Thursday, February 27th. They set a “buy” rating on the stock.

About Cellectis

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.